Can the drug prevent Alzheimer’s disease decades before it occurs?

A clinical trial that may take decades to be completely completed but may have changed results. The researchers test a medicine for plaque design for Alzheimer’s disease in young people who are genetically heading to develop devastating brain disorder.

Researchers are led at the Faculty of Medicine at Washington University Ticket,, Which tests an experimental antibody being developed by the ALI Lilly drug company. The medicine is given to people who are not exceeding the age of 18 years and who are at great early risk to the tooth. Although it may take up to 25 years to see if these medications can work as required, it will take much less time to gain some valuable ideas about the nature of Alzheimer’s, the researchers say.

The drug used in the tritnetug experiment is called. It aims to be a successor to Eli Lilly’s Donanemab (Kisunla brand), which was consent To treat early Alzheimer’s disease in July 2024. Donaneemab and Remternetug try to treat Alzheimer’s disease by targeting a mixed version of the beta amyloid protein. In people with Alzheimer’s disease, this wrong amyloid experimental accumulation accumulates in the brain, and they ultimately form the Hardy blocks known as paintings (another mixed protein, Tao, also plays a major role in causing Alzheimer’s disease).

While anti -melanoid drugs are the first approved treatments believed to delay the progress of Alzheimer’s disease, the current treatments have a Modest. It is known that amyloid plates can start building in the brain 20 or more before someone begins to show signs of Alzheimer’s. This leads to speculation that these drugs may be largely more effective and can completely prevent Alzheimer’s disease if given to people at risk during the previous time frame-a hypothesis that this latest experience aims to test directly.

The study, called the initial prevention experience, will record 240 people who are known to carry mutations in one of the three genes that always lead to early Alzheimer’s disease. It will include people who carry these mutations as well as non -pregnant relatives who will work as a type of control group. People are eligible to reach the study if they are smaller than 11 to 25 years of age, who are expected to develop Alzheimer’s disease based on the history of their families (this usually happens in the 1930s, 1940s or 1950s).

The main part of the experiment will run for two years, with randomly for the participants to receive the medicine or imaginary medicine every three months. After that, people will be able to take the medicine publicly for another four years if they choose it. Since the volunteers are very young, researchers do not expect to see any changes in their awareness during the trial. But they will be able to know if Remternetug can remarkably slow down or even stop the accumulation of amyloid plate in people’s brains.

Hannah Richardson, 24, said she is participating in the primary protection trial in A. statement Introduction from the Faculty of Medicine at the University of Washington. “I am pleased to participate in the experience of primary prevention and participation in research because I know how important this is.”

The researchers say that it will take nearly four to five years to report results from the first stage controlled by the imaginary medicine from the experiment, while the entire study is on the right path to be completed by 2034. But they are planning to monitor these patients over many years after that. The lessons we learn from this research are likely to help scientists understand the best Alzheimer’s player.

Maria C Carillo, chief science official at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at the Association Al -Zeheimer’s, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, at Al -Zheimer’s Association, “This innovative study in this population Patients of Alzheimer’s special disease, this patient’s patient with this patient’s patient with Alzheimer’s has the ability to influence greatly on how to prevent Alzheimer’s disease, and save individuals and families from the pain of this deadly disease. ” statement.